DOCSLIB.ORG

Conditions Contributing to Deaths Involving COVID-19, by Age Group, United States

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Conditions contributing to deaths involving COVID-19, by age group, United States. Week ending 2/1/2020 to 12/5/2020. Data as of 12/6/2020 Source: National Center for Health Statistics. National Vital Statistics System. Provisional data. 2020. This table shows the types of health conditions and contributing causes mentioned in conjunction with deaths involving coronavirus disease 2019 (COVID-19). For 6% of the deaths, COVID-19 was the only cause mentioned. For deaths with conditions or causes in addition to COVID-19, on average, there were 2.9 additional conditions or causes per death. The number of deaths with each condition or cause is shown for all deaths and by age groups. Values in the table represent number of deaths that mention the condition listed and 94% of deaths mention more than one condition. As such, the rows should not be summed. Additional notes are listed at the end of the table. Number of Conditions Age Group 0-24 25-34 35-44 45-54 55-64 65-74 75-84 85+ Condition ICD-10 Code Description All Ages Years Years Years Years Years Years Years Years COVID-19 U07.1 COVID-19 255508 535 1884 4840 12862 31400 54758 68966 80257 Conditions mentioned in conjunction with COVID-19 Influenza due to certain identified influenza Influenza and pneumonia J09.0 virus 1 0 0 0 0 0 0 1 0 Influenza with pneumonia, influenza virus Influenza and pneumonia J10.0 identified 64 0 2 1 4 10 16 18 13 Influenza with other respiratory Influenza and pneumonia J10.1 manifestations, influenza virus identified 53 0 1 2 3 8 13 11 15 Influenza with other manifestations, Influenza and pneumonia J10.8 influenza virus identified 2 0 0 0 1 0 0 1 0 Influenza with pneumonia, virus not Influenza and pneumonia J11.0 identified 50 0 1 2 0 8 14 9 16 Influenza with other respiratory Influenza and pneumonia J11.1 manifestations, virus not identified 867 4 11 26 101 196 209 178 142 Influenza with other respiratory Influenza and pneumonia J11.10 manifestations, virus not identified 3 0 0 0 0 1 0 2 0 Influenza with other manifestations, virus not Influenza and pneumonia J11.8 identified 3 0 0 0 0 0 1 1 1 Influenza and pneumonia J12.1 Respiratory syncytial virus pneumonia 4 0 0 0 0 1 1 1 1 Influenza and pneumonia J12.3 Human metapneumovirus pneumonia 1 0 0 0 0 0 1 0 0 Influenza and pneumonia J12.8 Other viral pneumonia 119 0 0 0 9 17 29 29 35 Influenza and pneumonia J12.9 Viral pneumonia, unspecified 9279 10 72 176 502 1185 2192 2519 2623 Pneumonia due to Streptococcus Influenza and pneumonia J13.0 pneumoniae 55 0 2 2 3 14 11 9 14 Influenza and pneumonia J14.0 Pneumonia due to Haemophilus influenzae 10 0 0 0 0 3 4 2 1 Number of Conditions Age Group 0-24 25-34 35-44 45-54 55-64 65-74 75-84 85+ Condition ICD-10 Code Description All Ages Years Years Years Years Years Years Years Years Influenza and pneumonia J15.0 Pneumonia due to Klebsiella pneumoniae 220 1 5 5 30 50 64 50 15 Influenza and pneumonia J15.1 Pneumonia due to Pseudomonas 368 1 2 8 41 83 127 81 25 Influenza and pneumonia J15.2 Pneumonia due to staphylococcus 674 1 7 26 60 165 220 138 57 Influenza and pneumonia J15.3 Pneumonia due to streptococcus, group B 5 0 0 0 0 1 1 1 2 Influenza and pneumonia J15.4 Pneumonia due to other streptococci 84 0 1 4 10 17 19 21 12 Influenza and pneumonia J15.5 Pneumonia due to Escherichia coli 56 0 0 0 7 18 14 13 4 Pneumonia due to other aerobic Gram- Influenza and pneumonia J15.6 negative bacteria 136 1 3 3 15 40 39 28 7 Influenza and pneumonia J15.7 Pneumonia due to Mycoplasma pneumoniae 39 0 1 0 4 4 6 18 6 Influenza and pneumonia J15.8 Other bacterial pneumonia 48 0 0 2 10 16 10 8 2 Influenza and pneumonia J15.9 Bacterial pneumonia, unspecified 1357 3 10 25 76 207 351 372 313 Influenza and pneumonia J18.0 Bronchopneumonia, unspecified 545 1 9 15 46 80 126 124 144 Influenza and pneumonia J18.1 Lobar pneumonia, unspecified 534 0 5 13 36 80 120 146 134 Influenza and pneumonia J18.2 Hypostatic pneumonia, unspecified 72 0 1 1 2 12 8 17 31 Influenza and pneumonia J18.8 Other pneumonia, organism unspecified 3 0 0 0 0 1 1 1 0 Influenza and pneumonia J18.9 Pneumonia, unspecified 96314 153 720 1863 5260 13078 22152 26459 26626 Chronic lower respiratory diseases J40.0 Bronchitis, not specified as acute or chronic 98 2 1 2 4 12 21 19 37 Chronic lower respiratory diseases J41.0 Simple chronic bronchitis 1 0 0 0 0 0 0 1 0 Chronic lower respiratory diseases J41.1 Mucopurulent chronic bronchitis 1 0 0 0 0 0 0 1 0 Chronic lower respiratory diseases J42.0 Unspecified chronic bronchitis 85 0 0 3 5 9 21 17 30 Chronic lower respiratory diseases J43.1 Panlobular emphysema 7 0 0 0 0 0 2 1 4 Chronic lower respiratory diseases J43.2 Centrilobular emphysema 22 0 0 0 0 0 6 9 7 Chronic lower respiratory diseases J43.8 Other emphysema 1 0 0 0 0 0 0 1 0 Chronic lower respiratory diseases J43.9 Emphysema, unspecified 775 0 0 2 14 76 202 258 222 Chronic obstructive pulmonary disease with Chronic lower respiratory diseases J44.0 acute lower respiratory infection 8448 1 4 15 111 777 2155 3057 2328 Chronic obstructive pulmonary disease with Chronic lower respiratory diseases J44.1 acute exacerbation, unspecified 572 0 0 1 7 55 160 203 146 Other specified chronic obstructive Chronic lower respiratory diseases J44.8 pulmonary disease 201 1 1 3 13 29 49 49 56 Number of Conditions Age Group 0-24 25-34 35-44 45-54 55-64 65-74 75-84 85+ Condition ICD-10 Code Description All Ages Years Years Years Years Years Years Years Years Chronic obstructive pulmonary disease, Chronic lower respiratory diseases J44.9 unspecified 10051 0 2 20 124 806 2311 3369 3419 Chronic lower respiratory diseases J45.0 Predominantly allergic asthma 11 9 0 0 1 0 1 0 0 Chronic lower respiratory diseases J45.9 Asthma, unspecified 2735 22 79 156 315 556 628 530 449 Chronic lower respiratory diseases J46.0 Status asthmaticus 4 1 1 0 0 1 1 0 0 Chronic lower respiratory diseases J47.0 Bronchiectasis 121 0 0 1 0 13 20 36 51 Adult respiratory distress syndrome J80.0 Adult respiratory distress syndrome 31113 86 328 895 2527 5582 8367 7667 5659 Respiratory failure J96.0 Acute respiratory failure 50728 79 349 867 2603 6586 11978 14618 13647 Respiratory failure J96.1 Chronic respiratory failure 2378 7 9 27 77 276 586 774 622 Respiratory failure J96.9 Respiratory failure, unspecified 37683 67 255 688 2046 4978 8760 10419 10469 Respiratory arrest R09.2 Respiratory arrest 5276 10 38 88 234 580 1062 1427 1837 Other diseases of the respiratory system J02.0 Streptococcal pharyngitis 6 0 1 2 0 2 1 0 0 Other diseases of the respiratory system J02.9 Acute pharyngitis, unspecified 5 0 1 1 0 0 0 2 1 Other diseases of the respiratory system J04.0 Acute laryngitis 1 0 0 0 0 0 1 0 0 Other diseases of the respiratory system J04.1 Acute tracheitis 3 0 0 0 1 1 0 0 1 Other diseases of the respiratory system J05.1 Acute epiglottitis 1 0 0 0 0 1 0 0 0 Other diseases of the respiratory system J06.0 Acute laryngopharyngitis 1 0 0 0 0 0 1 0 0 Acute upper respiratory infection, Other diseases of the respiratory system J06.9 unspecified 103 1 2 5 5 5 10 23 52 Acute bronchitis due to other specified Other diseases of the respiratory system J20.8 organisms 3 0 0 1 0 0 0 1 1 Other diseases of the respiratory system J20.9 Acute bronchitis, unspecified 38 0 0 0 0 3 5 12 18 Other diseases of the respiratory system J21.9 Acute bronchiolitis, unspecified 2 0 0 0 0 1 0 1 0 Other diseases of the respiratory system J22.0 Unspecified acute lower respiratory infection 196 1 2 5 6 7 34 49 92 Number of Conditions Age Group 0-24 25-34 35-44 45-54 55-64 65-74 75-84 85+ Condition ICD-10 Code Description All Ages Years Years Years Years Years Years Years Years Other diseases of the respiratory system J30.1 Allergic rhinitis due to pollen 2 0 0 0 0 0 1 0 1 Other diseases of the respiratory system J30.3 Other allergic rhinitis 1 0 0 0 0 0 1 0 0 Other diseases of the respiratory system J30.4 Allergic rhinitis, unspecified 9 0 0 0 0 2 1 1 5 Other diseases of the respiratory system J31.0 Chronic rhinitis 1 0 0 0 0 0 0 0 1 Other diseases of the respiratory system J32.0 Chronic maxillary sinusitis 1 0 0 0 0 0 0 1 0 Other diseases of the respiratory system J32.3 Chronic sphenoidal sinusitis 1 0 0 0 0 0 0 1 0 Other diseases of the respiratory system J32.4 Chronic pansinusitis 1 0 0 0 0 1 0 0 0 Other diseases of the respiratory system J32.9 Chronic sinusitis, unspecified 10 0 0 0 1 2 3 3 1 Other diseases of the respiratory system J33.9 Nasal polyp, unspecified 2 0 0 0 0 1 0 0 1 Other specified disorders of nose and nasal Other diseases of the respiratory system J34.8 sinuses 1 0 0 0 0 0 0 1 0 Chronic disease of tonsils and adenoids, Other diseases of the respiratory system J35.9 unspecified 3 0 0 0 0 0 3 0 0 Other diseases of the respiratory system J38.0 Paralysis of vocal cords and larynx 4 0 0 0 0 0 2 2 0 Other diseases of the respiratory system J38.3 Other diseases of vocal cords 1 0 1 0 0 0 0 0 0 Other diseases of the respiratory system J38.5 Laryngeal spasm 1 0 0 0 0 1 0 0 0 Other diseases of the respiratory system J38.6 Stenosis of larynx 3 2 0 1 0 0 0 0 0 Other diseases of the respiratory system J38.7 Other diseases of larynx 5 0 0 0 0 1 3 0 1 Other diseases of the respiratory system J39.2 Other diseases of pharynx 3 0 0 0 0 0 2 0 1 Number of Conditions Age Group 0-24 25-34 35-44 45-54 55-64 65-74 75-84 85+ Condition ICD-10 Code Description All Ages Years Years Years Years Years Years Years Years Other specified diseases of upper respiratory Other diseases of the respiratory system J39.8 tract 38 2 2 0 3 7 12 9 3 Disease of upper respiratory tract, Other diseases of the respiratory system
Recommended publications
  • Unusual Case of Primary Spontaneous Hemopneumothorax in a Young Man with Atypical Tension Pneumothorax: a Case Report Youwen Chen* and Zhijian Guo

    Unusual Case of Primary Spontaneous Hemopneumothorax in a Young Man with Atypical Tension Pneumothorax: a Case Report Youwen Chen* and Zhijian Guo

    Chen and Guo Journal of Medical Case Reports (2018) 12:188 https://doi.org/10.1186/s13256-018-1732-x CASE REPORT Open Access Unusual case of primary spontaneous hemopneumothorax in a young man with atypical tension pneumothorax: a case report Youwen Chen* and Zhijian Guo Abstract Background: Spontaneous life-threatening hemopneumothorax is an atypical but treatable entity of unexpected circulatory collapse in young patients, affecting 0.5–11.6% of patients with primary spontaneous pneumothorax. Spontaneous pneumothorax is a well-documented disorder with a classic clinical presentation of acute onset chest pain and shortness of breath. This disorder might be complicated by the development of hemopneumothorax or tension pneumothorax. Case presentation: A 23-year-old Asian man was referred to the emergency room of Xiamen Chang Gung Memorial Hospital with a 1-day history of right-sided chest pain that had been aggravated for 1 hour. A physical examination revealed a young man who was awake and alert but in mild to moderate painful distress. His vital parameters were relatively stable at first. The examining physician noted slight tenderness along the right posterolateral chest wall along the eighth and tenth ribs. Primary spontaneous pneumothorax was considered, and a standing chest X-ray confirmed the diagnosis. A right thoracostomy tube was immediately placed under sterile conditions, and he was referred to the respiratory service. While in the respiratory department, approximately 420 mL of blood was drained from the thoracostomy tube over 15 minutes. Our patient developed obvious hemodynamic instability with hypovolemic shock and was subsequently admitted to the cardiothoracic surgical ward after fluid resuscitation.
  • ICD10 Diagnoses FY2018 AHD.Com

    ICD10 Diagnoses FY2018 AHD.Com

    ICD10 Diagnoses FY2018 AHD.com A020 Salmonella enteritis A5217 General paresis B372 Candidiasis of skin and nail A040 Enteropathogenic Escherichia coli A523 Neurosyphilis, unspecified B373 Candidiasis of vulva and vagina infection A528 Late syphilis, latent B3741 Candidal cystitis and urethritis A044 Other intestinal Escherichia coli A530 Latent syphilis, unspecified as early or B3749 Other urogenital candidiasis infections late B376 Candidal endocarditis A045 Campylobacter enteritis A539 Syphilis, unspecified B377 Candidal sepsis A046 Enteritis due to Yersinia enterocolitica A599 Trichomoniasis, unspecified B3781 Candidal esophagitis A047 Enterocolitis due to Clostridium difficile A6000 Herpesviral infection of urogenital B3789 Other sites of candidiasis A048 Other specified bacterial intestinal system, unspecified B379 Candidiasis, unspecified infections A6002 Herpesviral infection of other male B380 Acute pulmonary coccidioidomycosis A049 Bacterial intestinal infection, genital organs B381 Chronic pulmonary coccidioidomycosis unspecified A630 Anogenital (venereal) warts B382 Pulmonary coccidioidomycosis, A059 Bacterial foodborne intoxication, A6920 Lyme disease, unspecified unspecified unspecified A7740 Ehrlichiosis, unspecified B387 Disseminated coccidioidomycosis A080 Rotaviral enteritis A7749 Other ehrlichiosis B389 Coccidioidomycosis, unspecified A0811 Acute gastroenteropathy due to A879 Viral meningitis, unspecified B399 Histoplasmosis, unspecified Norwalk agent A938 Other specified arthropod-borne viral B440 Invasive pulmonary
  • Educational Achievement and Economic Self-Sufficiency in Adults After Childhood Bacterial Meningitis

    Educational Achievement and Economic Self-Sufficiency in Adults After Childhood Bacterial Meningitis

    1 Supplementary Online Content Roed C, Omland LH, Skinhoj P, Rothman KJ, Sorensen HT, Obel N. Educational achievement and economic self-sufficiency in adults after childhood bacterial meningitis. JAMA. doi:10.1001/jama.2013.3792 Appendix 1. Description of Registries Appendix 2. Diagnosis Codes for Intrauterine and Birth Asphyxia or Chromosomal Abnormalities Appendix 3. Diagnosis Codes for Meningococcal, Pneumococcal, Or H influenzae Meningitis Appendix 4. Diagnosis Codes for Neuroinfections Other Than Bacterial Meningitis eTable 1. Number of Events in the Study Population and Total Observation Time eTable 2. Estimated Prevalence at Age 35 of Vocational Education, High School, Higher Education, Economic Self‐sufficiency and Disability pension Among Meningitis Patients, Members of the Population Comparison Cohorts, and Their Siblings Without Neonatal Morbidity eFigure 1. Cumulative Incidence of Having Been Economically Self‐sufficient for a Year and of Receiving Disability Pension in the Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Siblings of Members of the Population Comparison Cohort (Blue) eFigure 2. Cumulative Incidence of Vocational Education, High School and Higher Education for Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Full Siblings of Members of the Population Comparison Cohort (Blue) Born Before 1980 eFigure 3. Cumulative Incidence of Vocational Education, High School and Higher Education for Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Full Siblings of Members of the Population Comparison Cohort (Blue) Born After 1980 This supplementary material has been provided by the authors to give readers additional information about their work.
  • N35.12 Postinfective Urethral Stricture, NEC, Female N35.811 Other

    N35.12 Postinfective Urethral Stricture, NEC, Female N35.811 Other

    N35.12 Postinfective urethral stricture, NEC, female N35.811 Other urethral stricture, male, meatal N35.812 Other urethral bulbous stricture, male N35.813 Other membranous urethral stricture, male N35.814 Other anterior urethral stricture, male, anterior N35.816 Other urethral stricture, male, overlapping sites N35.819 Other urethral stricture, male, unspecified site N35.82 Other urethral stricture, female N35.911 Unspecified urethral stricture, male, meatal N35.912 Unspecified bulbous urethral stricture, male N35.913 Unspecified membranous urethral stricture, male N35.914 Unspecified anterior urethral stricture, male N35.916 Unspecified urethral stricture, male, overlapping sites N35.919 Unspecified urethral stricture, male, unspecified site N35.92 Unspecified urethral stricture, female N36.0 Urethral fistula N36.1 Urethral diverticulum N36.2 Urethral caruncle N36.41 Hypermobility of urethra N36.42 Intrinsic sphincter deficiency (ISD) N36.43 Combined hypermobility of urethra and intrns sphincter defic N36.44 Muscular disorders of urethra N36.5 Urethral false passage N36.8 Other specified disorders of urethra N36.9 Urethral disorder, unspecified N37 Urethral disorders in diseases classified elsewhere N39.0 Urinary tract infection, site not specified N39.3 Stress incontinence (female) (male) N39.41 Urge incontinence N39.42 Incontinence without sensory awareness N39.43 Post-void dribbling N39.44 Nocturnal enuresis N39.45 Continuous leakage N39.46 Mixed incontinence N39.490 Overflow incontinence N39.491 Coital incontinence N39.492 Postural
  • Guidelines for Treating Dissociative Identity Disorder in Adults, Third

    Guidelines for Treating Dissociative Identity Disorder in Adults, Third

    This article was downloaded by: [208.78.151.82] On: 21 October 2011, At: 09:20 Publisher: Routledge Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK Journal of Trauma & Dissociation Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/wjtd20 Guidelines for Treating Dissociative Identity Disorder in Adults, Third Revision International Society for the Study of Trauma and Dissociation Available online: 03 Mar 2011 To cite this article: International Society for the Study of Trauma and Dissociation (2011): Guidelines for Treating Dissociative Identity Disorder in Adults, Third Revision, Journal of Trauma & Dissociation, 12:2, 115-187 To link to this article: http://dx.doi.org/10.1080/15299732.2011.537247 PLEASE SCROLL DOWN FOR ARTICLE Full terms and conditions of use: http://www.tandfonline.com/page/terms-and-conditions This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.
  • A Review of the Evidence for and Against a Role for Mast Cells in Cutaneous Scarring and Fibrosis

    A Review of the Evidence for and Against a Role for Mast Cells in Cutaneous Scarring and Fibrosis

    International Journal of Molecular Sciences Review A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis Traci A. Wilgus 1,*, Sara Ud-Din 2 and Ardeshir Bayat 2,3 1 Department of Pathology, Ohio State University, Columbus, OH 43210, USA 2 Centre for Dermatology Research, NIHR Manchester Biomedical Research Centre, Plastic and Reconstructive Surgery Research, University of Manchester, Manchester M13 9PT, UK; [email protected] (S.U.-D.); [email protected] (A.B.) 3 MRC-SA Wound Healing Unit, Division of Dermatology, University of Cape Town, Observatory, Cape Town 7945, South Africa * Correspondence: [email protected]; Tel.: +1-614-366-8526 Received: 1 October 2020; Accepted: 12 December 2020; Published: 18 December 2020 Abstract: Scars are generated in mature skin as a result of the normal repair process, but the replacement of normal tissue with scar tissue can lead to biomechanical and functional deficiencies in the skin as well as psychological and social issues for patients that negatively affect quality of life. Abnormal scars, such as hypertrophic scars and keloids, and cutaneous fibrosis that develops in diseases such as systemic sclerosis and graft-versus-host disease can be even more challenging for patients. There is a large body of literature suggesting that inflammation promotes the deposition of scar tissue by fibroblasts. Mast cells represent one inflammatory cell type in particular that has been implicated in skin scarring and fibrosis. Most published studies in this area support a pro-fibrotic role for mast cells in the skin, as many mast cell-derived mediators stimulate fibroblast activity and studies generally indicate higher numbers of mast cells and/or mast cell activation in scars and fibrotic skin.
  • Neuropsychological Testing

    Neuropsychological Testing

    Medical Coverage Policy Effective Date ............................................. 8/15/2021 Next Review Date ....................................... 8/15/2022 Coverage Policy Number .................................. 0258 Neuropsychological Testing Table of Contents Related Coverage Resources Overview .............................................................. 1 Attention-Deficit/Hyperactivity Disorder: Assessment Coverage Policy ................................................... 1 and Treatment General Background ............................................ 2 Autism Spectrum Disorder/Pervasive Developmental Medicare Coverage Determinations .................. 15 Disorders: Assessment and Treatment Coding/Billing Information .................................. 16 Cognitive Rehabilitation Lyme Disease Treatment— Antibiotic Treatment References ........................................................ 28 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary
  • Topical Treatments for Seborrheic Keratosis: a Systematic Review

    Topical Treatments for Seborrheic Keratosis: a Systematic Review

    SYSTEMATIC REVIEW AND META-ANALYSIS Topical Treatments for Seborrheic Keratosis: A Systematic Review Ma. Celina Cephyr C. Gonzalez, Veronica Marie E. Ramos and Cynthia P. Ciriaco-Tan Department of Dermatology, College of Medicine and Philippine General Hospital, University of the Philippines Manila ABSTRACT Background. Seborrheic keratosis is a benign skin tumor removed through electrodessication, cryotherapy, or surgery. Alternative options may be beneficial to patients with contraindications to standard treatment, or those who prefer a non-invasive approach. Objectives. To determine the effectiveness and safety of topical medications on seborrheic keratosis in the clearance of lesions, compared to placebo or standard therapy. Methods. Studies involving seborrheic keratosis treated with any topical medication, compared to cryotherapy, electrodessication or placebo were obtained from MEDLINE, HERDIN, and Cochrane electronic databases from 1990 to June 2018. Results. The search strategy yielded sixty articles. Nine publications (two randomized controlled trials, two non- randomized controlled trials, three cohort studies, two case reports) covering twelve medications (hydrogen peroxide, tacalcitol, calcipotriol, maxacalcitol, ammonium lactate, tazarotene, imiquimod, trichloroacetic acid, urea, nitric-zinc oxide, potassium dobesilate, 5-fluorouracil) were identified. The analysis showed that hydrogen peroxide 40% presented the highest level of evidence and was significantly more effective in the clearance of lesions compared to placebo. Conclusion. Most of the treatments reviewed resulted in good to excellent lesion clearance, with a few well- tolerated minor adverse events. Topical therapy is a viable option; however, the level of evidence is low. Standard invasive therapy remains to be the more acceptable modality. Key Words: seborrheic keratosis, topical, systematic review INTRODUCTION Description of the condition Seborrheic keratoses (SK) are very common benign tumors of the hair-bearing skin, typically seen in the elderly population.
  • Comorbid Psychiatric Disorders in Children with Autism: Interview Development and Rates of Disorders

    Comorbid Psychiatric Disorders in Children with Autism: Interview Development and Rates of Disorders

    J Autism Dev Disord (2006) 36:849–861 DOI 10.1007/s10803-006-0123-0 ORIGINAL PAPER Comorbid Psychiatric Disorders in Children with Autism: Interview Development and Rates of Disorders Ovsanna T. Leyfer Æ Susan E. Folstein Æ Susan Bacalman Æ Naomi O. Davis Æ Elena Dinh Æ Jubel Morgan Æ Helen Tager-Flusberg Æ Janet E. Lainhart Published online: 15 July 2006 Ó Springer Science+Business Media, Inc. 2006 Abstract The Kiddie Schedule for Affective Disorders sample demonstrated a high prevalence of specific phobia, and Schizophrenia was modified for use in children and obsessive compulsive disorder, and ADHD. The rates of adolescents with autism by developing additional screening psychiatric disorder in autism are high and are associated questions and coding options that reflect the presentation of with functional impairment. psychiatric disorders in autism spectrum disorders. The modified instrument, the Autism Comorbidity Interview- Keywords Psychopathology Æ Autism Æ Psychiatric Present and Lifetime Version (ACI-PL), was piloted and interview Æ Comorbidity frequently diagnosed disorders, depression, ADHD, and OCD, were tested for reliability and validity. The ACI-PL provides reliable DSM diagnoses that are valid based on clinical psychiatric diagnosis and treatment history. The Children with autism frequently have problematic emo- tional reactions and behaviors along with the features that O. T. Leyfer Department of Psychological and Brain Sciences, University define autism. Disturbances of emotion, attention, activity, of Louisville, Louisville, KY, USA and thought, and associated behavioral problems occur in children with autism of all ages (Lainhart, 1999). It is not S. E. Folstein yet known how often these additional difficulties are due to Department of Psychiatry, Johns Hopkins University, Baltimore, MD, USA comorbid psychiatric disorders.
  • COVID-19 Pneumonia: the Great Radiological Mimicker

    COVID-19 Pneumonia: the Great Radiological Mimicker

    Duzgun et al. Insights Imaging (2020) 11:118 https://doi.org/10.1186/s13244-020-00933-z Insights into Imaging EDUCATIONAL REVIEW Open Access COVID-19 pneumonia: the great radiological mimicker Selin Ardali Duzgun* , Gamze Durhan, Figen Basaran Demirkazik, Meltem Gulsun Akpinar and Orhan Macit Ariyurek Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread worldwide since December 2019. Although the reference diagnostic test is a real-time reverse transcription-polymerase chain reaction (RT-PCR), chest-computed tomography (CT) has been frequently used in diagnosis because of the low sensitivity rates of RT-PCR. CT fndings of COVID-19 are well described in the literature and include predominantly peripheral, bilateral ground-glass opacities (GGOs), combination of GGOs with consolida- tions, and/or septal thickening creating a “crazy-paving” pattern. Longitudinal changes of typical CT fndings and less reported fndings (air bronchograms, CT halo sign, and reverse halo sign) may mimic a wide range of lung patholo- gies radiologically. Moreover, accompanying and underlying lung abnormalities may interfere with the CT fndings of COVID-19 pneumonia. The diseases that COVID-19 pneumonia may mimic can be broadly classifed as infectious or non-infectious diseases (pulmonary edema, hemorrhage, neoplasms, organizing pneumonia, pulmonary alveolar proteinosis, sarcoidosis, pulmonary infarction, interstitial lung diseases, and aspiration pneumonia). We summarize the imaging fndings of COVID-19 and the aforementioned lung pathologies that COVID-19 pneumonia may mimic. We also discuss the features that may aid in the diferential diagnosis, as the disease continues to spread and will be one of our main diferential diagnoses some time more.
  • Clinical Study Outcome of Concurrent Occult Hemothorax and Pneumothorax in Trauma Patients Who Required Assisted Ventilation

    Clinical Study Outcome of Concurrent Occult Hemothorax and Pneumothorax in Trauma Patients Who Required Assisted Ventilation

    Hindawi Publishing Corporation Emergency Medicine International Volume 2015, Article ID 859130, 6 pages http://dx.doi.org/10.1155/2015/859130 Clinical Study Outcome of Concurrent Occult Hemothorax and Pneumothorax in Trauma Patients Who Required Assisted Ventilation Ismail Mahmood,1 Zainab Tawfeek,2 Ayman El-Menyar,3,4,5 Ahmad Zarour,1 Ibrahim Afifi,1 Suresh Kumar,1 Ruben Peralta,1 Rifat Latifi,1 and Hassan Al-Thani1 1 Department of Surgery, Section of Trauma Surgery, Hamad General Hospital, P.O. Box 3050, Doha, Qatar 2Department of Emergency, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar 3Clinical Research, Section of Trauma Surgery, Hamad General Hospital, Doha, Qatar 4ClinicalMedicine,WeillCornellMedicalSchool,P.O.Box24144,Doha,Qatar 5Internal Medicine, Ahmed Maher Teaching Hospital, Cairo, Egypt Correspondence should be addressed to Ismail Mahmood; [email protected] Received 26 October 2014; Accepted 3 February 2015 Academic Editor: Seiji Morita Copyright © 2015 Ismail Mahmood et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. The management and outcomes of occult hemopneumothorax in blunt trauma patients who required mechanical ventilation are not well studied. We aimed to study patients with occult hemopneumothorax on mechanical ventilation who could be carefully managed without tube thoracostomy. Methods. Chest trauma patients with occult hemopneumothorax who were on mechanical ventilation were prospectively evaluated. The presence of hemopneumothorax was confirmed by CT scanning. Hospital length of stay, complications, and outcome were recorded. Results.Atotalof56chesttraumapatientswithoccult hemopneumothorax who were on ventilatory support were included with a mean age of 36 ± 13 years.
  • ICD-10 Coordination and Maintenance Committee Meeting Diagnosis Agenda March 5-6, 2019 Part 2

    ICD-10 Coordination and Maintenance Committee Meeting Diagnosis Agenda March 5-6, 2019 Part 2

    ICD-10 Coordination and Maintenance Committee Meeting Diagnosis Agenda March 5-6, 2019 Part 2 Welcome and announcements Donna Pickett, MPH, RHIA Co-Chair, ICD-10 Coordination and Maintenance Committee Diagnosis Topics: Contents Babesiosis ........................................................................................................................................... 10 David, Berglund, MD Mikhail Menis, PharmD, MS Epi, MS PHSR Epidemiologist Office of Biostatistics and Epidemiology CBER/FDA C3 Glomerulopathy .......................................................................................................................... 13 David Berglund, MD Richard J. Hamburger, M.D. Professor Emeritus of Medicine, Indiana University Renal Physicians Association Eosinophilic Gastrointestinal Diseases ............................................................................................ 18 David Berglund, MD Bruce Bochner, MD Samuel M. Feinberg Professor of Medicine Northwestern University Feinberg School of Medicine and President, International Eosinophil Society ICD-10 Coordination and Maintenance Committee Meeting March 5-6, 2019 Food Insecurity.................................................................................................................................. 20 Donna Pickett Glut1 Deficiency ................................................................................................................................ 23 David Berglund, MD Hepatic Fibrosis ...............................................................................................................................